Survey response | n/N (%) |
Ideal timing* | |
<1 week | 11/24 (46%) |
1–4 weeks | 9/24 (38%) |
>4 weeks | 0/24 (0%) |
Unsure | 4/24 (17%) |
Ideal ulcer location for CXL* | |
Central | 6/24 (25%) |
Peripheral | 1/24 (4%) |
Does not matter | 13/24 (54%) |
Unsure | 4/24 (17%) |
CXL beneficial by infiltrate size | |
Small* | 17/24 (71%) |
Medium† | 16/23 (70%) |
Large† | 8/23 (35%) |
Would use CXL for corneal thinning | 15/25 (60%) |
Would use CXL for non-healing ulcer | 12/25 (48%) |
Main benefits of CXL | |
Microbial eradication | 21/25 (84%) |
Prevention of corneal thinning | 15/25 (60%) |
Other benefits | 3/25 (12%) |
*One respondent with missing data.
†Two respondents with missing data.
CXL, corneal cross-linking.